Strategic IP Focus LATITUDE Pharmaceuticals specializes in reformulation and IP-driven drug delivery technologies, creating out-license ready opportunities and 505(b)(2) NDA potential. This suggests a sales angle around advanced formulation capabilities, IP strategy services, and partnerships to monetize insoluble or unstable molecules.

CDMO Capabilities As a GMP-focused CDMO with expertise in insoluble and challenging compounds, LATITUDE can be positioned for contract formulation, process optimization, and scale-up support for biotech and pharma clients seeking robust manufacturing and regulatory-compliant solutions.

Revenue Growth Potential Current revenue is in the mid-range for midsize CRO/CMO players, indicating room to scale through expanded service lines, larger client engagements, or additional capacity. This presents cross-sell opportunities to existing biotechs and partnerships with mid-to-large pharma collaborators.

Acquisition History Former parent acquisition by BioVie indicates sensitivity to corporate transitions and potential integration considerations. Sales conversations can address continuity of programs, transfer of licenses, and ongoing support for programs previously under LAT Pharma.

Market Positioning Operating in a competitive CDMO landscape with peers of varying scale, LATITUDE can differentiate on specialized reformulation technologies and 505(b)(2) opportunities. Target prospects may include biotech firms seeking rapid route to clinic-ready formulations and strategic IP partnerships.